Fanny Lundmark
Uppsala, C, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Synthesis and preclinical evaluation of gastrin releasing peptide receptor antagonist [18F]MeTz-PEG2-RM26 for positron emission tomography.
Journal: EJNMMI radiopharmacy and chemistry
Published: January 28, 2025
Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker.
Journal: Molecular medicine reports
Published: August 25, 2023
177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry.
Journal: Frontiers in oncology
Published: May 11, 2023
The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity.
Journal: Diagnostics (Basel, Switzerland)
Published: April 08, 2023
Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation.
Journal: Cancers
Published: December 10, 2022
Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands.
Journal: Pharmaceutics
Published: April 26, 2022
Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model.
Journal: Pharmaceutics
Published: June 08, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026